Drug company pays $95 million to settle marketing suit
Germany-based pharmaceutical maker Boehringer Ingelheim Pharmaceuticals has settled a suit against it brought by the U.S. Department of Justice, which accused the company of marketing some of its drugs for unapproved uses.
October 26, 2012 at 07:21 AM
5 minute read
The original version of this story was published on Law.com
Germany-based pharmaceutical maker Boehringer Ingelheim Pharmaceuticals has settled a suit against it brought by the U.S. Department of Justice (DOJ), which accused the company of marketing some of its drugs for unapproved uses.
The DOJ announced yesterday that Boehringer will pay $95 million to resolve the allegations that it improperly promoted its anti-stroke drug Aggrenox, its chronic obstructive pulmonary disease drugs Atrovent and Combivent, and its hypertension drug Micardis. According to the DOJ, Boehringer marketed Aggrenox, for example, to treat certain types of heart problems when it was only approved to prevent strokes.
“The improper promotion of pharmaceuticals undermines the FDA's important role in protecting the American public by determining whether a drug is safe and effective for a particular use before it is marketed,” Stuart Delery, acting assistant attorney general for the DOJ's Civil Division, said in a statement. “Such improper conduct by pharmaceutical companies also causes the government to pay significant amounts for products for which it would not otherwise pay. This civil settlement by Boehringer demonstrates that such conduct will not be tolerated.”
Read more about this story on Thomson Reuters.
Read more InsideCounsel stories about pharmaceutical companies under fire for their marketing practices:
GSK agrees to unprecedented settlement, corporate integrity agreement
Johnson & Johnson to pay $181 million to settle Risperdal case
J&J and DOJ close to settlement in Risperdal case
Dr. Drew Pinsky paid by Glaxo to promote Wellbutrin
Glaxo agrees to pay $956.8 million criminal fine
Glaxo agrees to pay $3 billion to settle marketing probes
Former Glaxo lawyer indicted again over drug probe
Glaxo GC Accused of Obstructing Investigation
Germany-based pharmaceutical maker
The DOJ announced yesterday that Boehringer will pay $95 million to resolve the allegations that it improperly promoted its anti-stroke drug Aggrenox, its chronic obstructive pulmonary disease drugs Atrovent and Combivent, and its hypertension drug Micardis. According to the DOJ, Boehringer marketed Aggrenox, for example, to treat certain types of heart problems when it was only approved to prevent strokes.
“The improper promotion of pharmaceuticals undermines the FDA's important role in protecting the American public by determining whether a drug is safe and effective for a particular use before it is marketed,” Stuart Delery, acting assistant attorney general for the DOJ's Civil Division, said in a statement. “Such improper conduct by pharmaceutical companies also causes the government to pay significant amounts for products for which it would not otherwise pay. This civil settlement by Boehringer demonstrates that such conduct will not be tolerated.”
Read more about this story on Thomson Reuters.
Read more InsideCounsel stories about pharmaceutical companies under fire for their marketing practices:
GSK agrees to unprecedented settlement, corporate integrity agreement
J&J and DOJ close to settlement in Risperdal case
Dr. Drew Pinsky paid by Glaxo to promote Wellbutrin
Glaxo agrees to pay $956.8 million criminal fine
Glaxo agrees to pay $3 billion to settle marketing probes
Former Glaxo lawyer indicted again over drug probe
Glaxo GC Accused of Obstructing Investigation
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View All
Recent Controversial Decision and Insurance Law May Mitigate Exposure for Companies Subject to False Claims Act Lawsuits
7 minute read
Trending Stories
- 1ACC CLO Survey Waves Warning Flags for Boards
- 2States Accuse Trump of Thwarting Court's Funding Restoration Order
- 3Microsoft Becomes Latest Tech Company to Face Claims of Stealing Marketing Commissions From Influencers
- 4Coral Gables Attorney Busted for Stalking Lawyer
- 5Trump's DOJ Delays Releasing Jan. 6 FBI Agents List Under Consent Order
Who Got The Work
J. Brugh Lower of Gibbons has entered an appearance for industrial equipment supplier Devco Corporation in a pending trademark infringement lawsuit. The suit, accusing the defendant of selling knock-off Graco products, was filed Dec. 18 in New Jersey District Court by Rivkin Radler on behalf of Graco Inc. and Graco Minnesota. The case, assigned to U.S. District Judge Zahid N. Quraishi, is 3:24-cv-11294, Graco Inc. et al v. Devco Corporation.
Who Got The Work
Rebecca Maller-Stein and Kent A. Yalowitz of Arnold & Porter Kaye Scholer have entered their appearances for Hanaco Venture Capital and its executives, Lior Prosor and David Frankel, in a pending securities lawsuit. The action, filed on Dec. 24 in New York Southern District Court by Zell, Aron & Co. on behalf of Goldeneye Advisors, accuses the defendants of negligently and fraudulently managing the plaintiff's $1 million investment. The case, assigned to U.S. District Judge Vernon S. Broderick, is 1:24-cv-09918, Goldeneye Advisors, LLC v. Hanaco Venture Capital, Ltd. et al.
Who Got The Work
Attorneys from A&O Shearman has stepped in as defense counsel for Toronto-Dominion Bank and other defendants in a pending securities class action. The suit, filed Dec. 11 in New York Southern District Court by Bleichmar Fonti & Auld, accuses the defendants of concealing the bank's 'pervasive' deficiencies in regards to its compliance with the Bank Secrecy Act and the quality of its anti-money laundering controls. The case, assigned to U.S. District Judge Arun Subramanian, is 1:24-cv-09445, Gonzalez v. The Toronto-Dominion Bank et al.
Who Got The Work
Crown Castle International, a Pennsylvania company providing shared communications infrastructure, has turned to Luke D. Wolf of Gordon Rees Scully Mansukhani to fend off a pending breach-of-contract lawsuit. The court action, filed Nov. 25 in Michigan Eastern District Court by Hooper Hathaway PC on behalf of The Town Residences LLC, accuses Crown Castle of failing to transfer approximately $30,000 in utility payments from T-Mobile in breach of a roof-top lease and assignment agreement. The case, assigned to U.S. District Judge Susan K. Declercq, is 2:24-cv-13131, The Town Residences LLC v. T-Mobile US, Inc. et al.
Who Got The Work
Wilfred P. Coronato and Daniel M. Schwartz of McCarter & English have stepped in as defense counsel to Electrolux Home Products Inc. in a pending product liability lawsuit. The court action, filed Nov. 26 in New York Eastern District Court by Poulos Lopiccolo PC and Nagel Rice LLP on behalf of David Stern, alleges that the defendant's refrigerators’ drawers and shelving repeatedly break and fall apart within months after purchase. The case, assigned to U.S. District Judge Joan M. Azrack, is 2:24-cv-08204, Stern v. Electrolux Home Products, Inc.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
